Woonsocket

This research aims to learn more about how zuranolone affects postpartum depression PPD symptoms in adults who took the medication within one year after the end of their pregnancy. PPD can cause tiredness, sadness, and loss of interest in daily activities. The study is observational, collecting health information from participants who have already been prescribed zuranolone through CVS Specialty Pharmacy in the United States between June 2025 and May 2026. Participants will be contacted by email or phone after filling their zuranolone prescription to ask if they wish to join the study. Those who agree will complete questionnaires about their symptoms using the Edinburgh Postnatal Depression Scale EPDS and answer other surveys about their health and environment. Participants must take their first dose of zuranolone within seven days of joining. The study will follow them by collecting EPDS scores at baseline, Day 15, and Day 45, which is 30 days after treatment ends. Throughout the study, researchers will monitor changes in PPD symptoms using EPDS scores and assess breastfeeding status during treatment. They will also gather information about medication use before, during, and after zuranolone treatment. Participants will complete surveys independently, and the study focuses on understanding how zuranolone influences PPD symptoms over the 45-day period.

This research aims to evaluate a technology-based collaborative care model called RI-SPHERES among postpartum patients with hypertensive disorders of pregnancy HDP. The trial will test whether RI-SPHERES is not worse than a standard self-measured blood pressure SMBP program in controlling persistent hypertension six weeks after delivery and improving preventive care attendance within one year. The study addresses challenges like low adherence to blood pressure checks due to barriers such as childcare and transportation, especially in racial or ethnic minority groups. Participants will be randomly assigned to one of two groups the RI-SPHERES group or the standard SMBP program group. The RI-SPHERES group will use a LTE-enabled blood pressure cuff syncing to a smartphone app that sends automated reminders and adaptive messages based on blood pressure readings and symptoms, with a nurse practitioner-led collaborative care team supporting patients. The first six weeks focus on blood pressure control, then shift to preventive care support for up to one year. The standard SMBP group will manually enter blood pressure readings into an electronic record to be reviewed by clinical staff, with recommendations for monthly blood pressure checks and preventive care after six weeks postpartum. Participants will be involved for one year postpartum, during which blood pressure measurements, preventive care visits, and maternal health outcomes will be monitored. Assessments include short- and long-term blood pressure control, severe maternal morbidity, emergency visits, hospital readmissions, medication adjustments, and patient satisfaction. The study will also evaluate equity in care related to race, ethnicity, language, and geography. Data will be collected through the app, electronic medical records, and regular communications with the study team to track adherence and health outcomes.